BioSpace News Archive

Avanos Medical, Inc. (NYSE: AVNS) today reported fourth quarter and full-year 2022 results.

Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that it will host a conference call and webcast on Friday, March 3, 2023 , at 8:30 a.m. ET to discuss a corporate update and financial results for the fourth quarter and full year 2022.

Ascensia Diabetes Care, a global diabetes care company, maker of the CONTOUR® Blood Glucose Monitoring system portfolio and exclusive distributor of Eversense® Continuous Glucose Monitoring Systems, announces a landmark global collaboration with SNAQ, an award-winning app-based solution that offers key insights on food and nutrition for people with diabetes.

Syndax Pharmaceuticals, Inc. today announced that it will report its fourth quarter and year-end 2022 financial results and provide a business update on Tuesday, February 28, after the close of the U.S. financial markets.

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced additional positive interim data from a Phase 2 open-label extension (OLE) study of donidalorsen, an investigational antisense medicine for the treatment of patients with hereditary angioedema (HAE).

908 Devices Inc., (Nasdaq: MASS) a pioneer of handheld and desktop devices for chemical and biochemical analysis, today announced it will participate in the upcoming Cowen 43rd Annual Healthcare Conference in Boston, MA.

VUZE Medical, a privately-held company aiming to transform intra-operative guidance in minimally invasive spinal interventions, has successfully concluded a 20-patient clinical study for its VUZE System evaluating safety, accuracy and user experience at the Rambam Healthcare Campus, a 1,000-bed academic hospital in Haifa, Israel.

Avivagen Inc. today reported its audited financial results for the year ended October 31, 2022 and the implementation of a strategic plan to accelerate growth.

Palvella Therapeutics, Inc. today reported progress on its three lead development programs for QTORIN™ rapamycin.

Harmony Biosciences today reported financial results and business updates for the fourth quarter and full year ended December 31, 2022.